Everything Old Is New Again | GenomeWeb

Phenotypic screening is once again popular at many large pharmaceutical companies, as the targeted drug discovery approach is being considered too limiting in certain ways, says Joanne Kotz at SciBX. "Phenotypic screens used to be the mainstay of drug development," Kotz says. Since the 1980s, advances in molecular biology and genomics have led drug companies to use targeted screening method to develop drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.